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The recent identification of a biallelic RAD51C
(FANCO) mutation in a family with a Fanconi Anemia-
like disorder led to its examination in a large hereditary
breast and ovarian cancer case-control candidate study
(Meindl, et al., 2010; Vaz, et al., 2010). Meindl et al.
identified six independent pathogenic monoallelic muta-
tions. Interestingly, these mutations were identified
exclusively within 480 families with breast and ovarian
cancer (frequency 1.3%) but not among any of the 620
families with breast cancer only. In most subsequent
studies, the mutation frequency has been found to be
lower than 1.3%, with only three additional truncating
mutations being identified in five families among more
than 729 ovarian cancer families (with or without breast
c a n c e r )( A k b a r i ,e ta l . ,2 0 1 0 ;P a n g ,e ta l . ,2 0 1 1 ;P e l t t a r i ,
et al., 2011; Romero, et al., 2011; Silvestri, et al., 2011;
Wong, et al., 2011; Zheng, et al., 2010). Despite the pre-
sence of breast cancer in 10 of the 15 RAD51C mutation
positive families reported to date, analysis of more than
1,373 breast cancer-only families by eight studies collec-
tively has not identified any additional families with
truncating RAD51C mutations. Therefore, while evi-
d e n c eo fac a u s a t i v er o l ef o rRAD51C in breast and
ovarian or ovarian only cancer families (HBOC) is con-
vincing, albeit with low prevalence, its role in breast
cancer only (HBC) families remains unclear.
To provide more definitive data on the incidence of
RAD51C mutations in hereditary breast and ovarian
families, we utilised high resolution melt (HRM) analysis
to screen for germline mutations in all coding exons of
RAD51C in index cases from 1,388 non-BRCA1,n o n -
BRCA2 high risk Australian HBC and HBOC families,
and 427 controls. In addition, the contribution of
RAD51C in unselected ovarian cancer was examined
through the analysis of germline DNA from an unse-
lected cohort of 267 ovarian cancer patients.
Analysis of 1,053 HBC and 335 HBOC families, and
267 unselected ovarian cancer cases identified 12 novel
heterozygous variants in RAD51C, three of which were
protein truncating, six non-synonymous, one synon-
ymous and two non-coding. Numerous dbSNPs and var-
iants from previous studies were also identified. Two
truncating mutations, c.72_73insTGCGG (p.V25CfsX3)
and c.397C>T (p.Q133X), were identified amongst the
1,388 familial cases. Consistent with the previously
reported deleterious mutations, both variants were iden-
tified in families with at least one report of ovarian can-
cer. A third truncating variant, c.230delG (p.
G77VfsX24), was identified in a high grade serous
tumour among the 267 unselected ovarian cancer cases.
In silico analyses predict that four missense variants
(including two novel variants) are likely to be patho-
genic. Our data also provide support for the designation
of the previously reported missense variants p.G264S,
and possibly p.A126T, as moderate penetrance alleles.
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